Lilly shares rise on hopes that next-gen drug will extend lead in weight-loss market
June 8 (Reuters) - Eli Lilly shares rose 4% on Monday, driven by compelling new data for its next-generation obesity drug, retatrutide, with analysts and investors expecting it to extend the drugmaker's lead in the booming weight-loss market. Lilly pr...
#TopNews #News #Lilly #theAmericanDiabetesAssociation #RBCCapitalMarkets
